Winton Group’s Beam Therapeutics BEAM Stock Holding History

Winton Group’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,847	Closed	-$271K	–	790
2023 Q1	$271K	Buy	+8,847	New	+$349K	0.02%	846

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group's BEAM Position: Q2 2023 in Review

Winton Group sold out of Beam Therapeutics (BEAM) in Q2 2023, closing a stake of 8,847 shares — an estimated $271K sold.

Winton Group first reported a position in BEAM in Q1 2023 and held it in 1 quarter. The position peaked at $271K in Q1 2023. 193 funds tracked by Wall St. Rank hold BEAM as of Q2 2023.

Winton Group reported no remaining Beam Therapeutics position as of Q2 2023 after selling out during the quarter.
Winton Group sold 8,847 Beam Therapeutics shares in Q2 2023, an estimated $271K.
Winton Group first reported a position in Beam Therapeutics in Q1 2023 and held it in 1 quarter.
Winton Group's Beam Therapeutics position peaked at $271K in Q1 2023.
193 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2023.

Based on Winton Group's 13F filing for Q2 2023, filed 14 Aug 2023.